🇺🇸 Tyrosine kinase inhibitors in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 3
Most-reported reactions
- Amylase Increased — 1 report (33.33%)
- Systemic Lupus Erythematosus — 1 report (33.33%)
- Tumour Lysis Syndrome — 1 report (33.33%)
Frequently asked questions
Is Tyrosine kinase inhibitors approved in United States?
Tyrosine kinase inhibitors does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Tyrosine kinase inhibitors in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.